Bielak M, et al. - Experts assessed systemic juvenile idiopathic arthritis (sJIA) patients treated with the interleukin-6 (IL-6) inhibitor tocilizumab (TCZ) concerning clinical response rate, disease course and adverse impacts in a real-life clinical setting. As per data, among 200 sJIA children reported in the German autoinflammatory disease (AID)-registry, 46 were treated with TCZ, these patients, during the first 12 weeks, demonstrated a clinical response rate of 35%, and inactive disease and/or remission under medication in 75% after one year. In 24%, adverse events were seen and 4% demonstrated severe adverse events.